This suggests that the use of prophylactic G-CSF could be appropriate for a predefined subgroup of breast cancer patients with an increased risk of neutropenia such as the elderly, unstable patients and those with bone metastasis as observed in this current study. Here, CSF3 is linked to breast carcinoma.